Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jing Dong, Yuan-cheng Chen, Wei Xiong, Yun-feng Zhao, Ye-bin Sun, Yang Lu, Yan-hui Liu, Wen-yan Li & Xi-jing Chen. (2016) Efficacy and safety of biapenem against lower respiratory tract infections in elderly Chinese patients and optimal dosing regimen based on pharmacokinetic/pharmacodynamic analysis. Journal of Chemotherapy 28:5, pages 403-410.
Read now
Read now
Guangsheng Pei, Weijiao Yin, Yongmei Zhang, Tongsheng Wang, Yimin Mao & Yuxia Sun. (2016) Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials. Journal of Chemotherapy 28:1, pages 28-36.
Read now
Read now
Ioannis P Kioumis, Joseph L Kuti & David P Nicolau. (2007) Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opinion on Pharmacotherapy 8:2, pages 167-182.
Read now
Read now
Giuseppe Nicoletti, Giovanni Russo & Giovanni Bonfiglio. (2002) Recent developments in carbapenems. Expert Opinion on Investigational Drugs 11:4, pages 529-544.
Read now
Read now
Articles from other publishers (21)
S. V. YAKOVLEV & M. P. SUVOROVA. (2022) Biapenem: Clinical and Microbiological Characteristics and the Place of The New Carbapenem In The Treatment of Severe Infections In The Hospital. Clinical Pharmacologists' Point of View. Antibiotics and Chemotherapy 67:5-6, pages 81-91.
Crossref
Crossref
Xiuwen Wu, Jie Wu, Peige Wang, Xueling Fang, Yunsong Yu, Jianguo Tang, Yonghong Xiao, Minggui Wang, Shikuan Li, Yun Zhang, Bijie Hu, Tao Ma, Qiang Li, Zhiming Wang, Anhua Wu, Chang Liu, Menghua Dai, Xiaochun Ma, Huimin Yi, Yan Kang, Daorong Wang, Gang Han, Ping Zhang, Jianzhong Wang, Yufeng Yuan, Dong Wang, Jian Wang, Zheng Zhou, Zeqiang Ren, Yuxiu Liu, Xiangdong Guan & Jianan Ren. (2020) Diagnosis and Management of Intraabdominal Infection: Guidelines by the Chinese Society of Surgical Infection and Intensive Care and the Chinese College of Gastrointestinal Fistula Surgeons. Clinical Infectious Diseases 71:Supplement_4, pages S337-S362.
Crossref
Crossref
Lingyuan Chen, Xueyan Liang, Junsong Jiang, Xianshu Li & Yan Li. (2019) Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections. Medicine 98:40, pages e17436.
Crossref
Crossref
Kimberly A. Toussaint & Jason C. Gallagher. (2014) β-Lactam/β-Lactamase Inhibitor Combinations. Annals of Pharmacotherapy 49:1, pages 86-98.
Crossref
Crossref
Joan P. Cannon, Todd A. Lee, Nina M. Clark, Paul Setlak & Shellee A. Grim. (2014) The risk of seizures among the carbapenems: a meta-analysis. Journal of Antimicrobial Chemotherapy 69:8, pages 2043-2055.
Crossref
Crossref
Ellie J. C. Goldstein, Diane M. Citron, Kerin L. Tyrrell & C. Vreni Merriam. (2013)
In Vitro
Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria
. Antimicrobial Agents and Chemotherapy 57:6, pages 2620-2630.
Crossref
Crossref
Michael PfallerKunikazu Yamane. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
542
546
.
Michael PfallerYoshiro Hayashi & David Paterson. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
471
499
.
Yuko Muto, Yukio Mikami, Shiro Sakakibara, Atsuyuki Shimizu, Masashi Niida, Hiroshi Kataoka, Fumi Ito, Katsuyoshi Suzuki, Koji Kijima, Kazunori Maebashi, Toshihiko Takata, Muneo Hikida, Kazunori Takeda & Michiaki Unno. (2008) Pharmacokinetic and Pharmacodynamic Properties of Biapenem, a Carbapenem Antibiotic, in Rat Experimental Model of Severe Acute Pancreatitis. Pancreas 36:2, pages 125-132.
Crossref
Crossref
P.M. Shah. (2008) Parenteral carbapenems. Clinical Microbiology and Infection 14, pages 175-180.
Crossref
Crossref
Peng F Wong, Andrew D Gilliam, Senthil Kumar, Jonathan Shenfine, Graham N O'Dair & David J Leaper. (2005) Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Joseph S. Solomkin. 2003. Quinolone Antimicrobial Agents. Quinolone Antimicrobial Agents
217
225
.
John E. Mazuski, Robert G. Sawyer, Avery B. Nathens, Joseph T. DiPiro, Moshe Schein, Kenneth A. Kudsk & Charles Yowler. (2002) The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: Evidence for the Recommendations. Surgical Infections 3:3, pages 175-233.
Crossref
Crossref
Caroline M. Perry & Tim Ibbotson. (2002) Biapenem. Drugs 62:15, pages 2221-2234.
Crossref
Crossref
Eva Susanne Dietrich, Bj??rn Schubert, Winfried Ebner & Franz Daschner. (2001) Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection. PharmacoEconomics 19:1, pages 79-94.
Crossref
Crossref
H??lio S. Sader & Ana C. Gales. (2001) Emerging Strategies in Infectious Diseases. Drugs 61:5, pages 553-564.
Crossref
Crossref
Joseph S. Solomkin, Samuel E. Wilson, Nicholas V. Christou, Ori D. Rotstein, E. Patchen Dellinger, Robert S. Bennion, Raphael Pak & Kenneth Tack. (2001) Results of a Clinical Trial of Clinafloxacin Versus Imipenem/Cilastatin for Intraabdominal Infections. Annals of Surgery 233:1, pages 79-87.
Crossref
Crossref
Chukwuemeka S. Okereke. (2000) Advances in the use of carbapenem antibiotics in the management of serious bacterial infections in special patient populations. I: Safety and efficacy in children and elderly patients. Current Therapeutic Research 61:5, pages 289-320.
Crossref
Crossref
C. E. Nord. (1999) Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin. Infection 27:3, pages 166-172.
Crossref
Crossref
B. Brismar & C. E. Nord. (1999) Monobactams and carbapenems for treatment of intraabdominal infections. Infection 27:2, pages 136-147.
Crossref
Crossref
Giorgio Zanetti, Stephan Jürgen Harbarth, Andrej Trampuz, Marcus Ganeo, François Mosimann, Roland Chautemps, Pierre Morel, Daniel Lew, Werner Zimmerli, Jochen Lange & Michel Glauser. (1999) Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. International Journal of Antimicrobial Agents 11:2, pages 107-113.
Crossref
Crossref